Patient Capital Review – it may be of all-consuming interest to those who work in the tax-advantaged investment sector, however for those after summarising points, Jack Rose is happy to supply these.

For those of us who work within the tax-advantaged investment sector, the upcoming outcome of the Patient Capital Review (PCR) – all its possible permutations and consequences – is the talk of the town.

But for those who spend less time dwelling on tax legislation and rule changes within the sector (very wise if you ask me) are inclined to look blank when you mention the Patient Capital Review.

So for those who like a simple summary of the salient points, click here.

Source: ProfessionalAdviser

GET IN TOUCH!


  MAIL US
enquiries@growthinvest.com

  CALL US
020 7071 3945

FOLLOW US ON


Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.